Survodutide is the GLP-1/glucagon dual-agonist peptide that most people in the obesity pipeline have their eyes on, even though it is not yet a household name like semaglutide or tirzepatide. Developed by Boehringer Ingelheim in partnership with Zealand Pharma and carrying the development code BI 456906, survodutide represents a distinct mechanistic bet: that simultaneously activating the GLP-1 receptor and the glucagon receptor will unlock weight-loss and liver-fat benefits that a GLP-1 alone — or even a GLP-1/GIP combination — cannot reach.
The compound is currently in Phase 3 trials under the SYNCHRONIZE program for obesity and in late-stage trials for MASH (metabolic dysfunction-associated steatohepatitis, the new name for NASH). If the data holds, survodutide could become the first approved glucagon-receptor-activating obesity peptide, opening a new axis of metabolic drug design. This deep dive walks through the biology of dual agonism, the specific trial data that has generated the excitement, and how survodutide fits into an increasingly crowded pipeline.
⚕️ Regulatory notice. Survodutide is investigational. It is not approved by the FDA, EMA, or any other regulatory agency. It is being evaluated in Phase 3 clinical trials for obesity and MASH. Nothing in this article should be taken as medical or investment advice.
What Is Survodutide?
Survodutide is a synthetic peptide dual agonist of the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. Structurally, it is a long-acting peptide engineered from a glucagon backbone with sequence modifications and a fatty-acid lipidation that extends its plasma half-life to support once-weekly subcutaneous dosing.
The molecule was born out of Zealand Pharma's long-running work on glucagon-family peptide analogs. Zealand is a Copenhagen-based peptide specialist with deep expertise in glucagon biology — they also developed dasiglucagon, approved for hypoglycemia rescue. Zealand partnered with Boehringer Ingelheim, the German pharma company that had been systematically rebuilding its diabetes and metabolic franchise, and Boehringer took on clinical development as the lead sponsor. Boehringer contributed its large-scale development and commercial infrastructure; Zealand contributed the peptide chemistry.
Survodutide's dual mechanism is the point. GLP-1 alone reduces appetite and improves glucose control. Glucagon, somewhat counterintuitively, increases energy expenditure and mobilizes hepatic fat — so combining the two receptors targets weight loss through both reduced food intake and increased energy burn, plus direct effects on liver fat.
Mechanism of Action
To understand why dual agonism matters, it helps to look at the rapidly expanding landscape of incretin and glucagon-family drugs and what each mechanism contributes.
| Class | GLP-1R | GIPR | GCGR | Example | Status |
|---|---|---|---|---|---|
| GLP-1 single agonist | Yes | — | — | Semaglutide (Wegovy) | Approved |
| GLP-1 + GIP dual | Yes | Yes | — | Tirzepatide (Zepbound) | Approved |
| GLP-1 + glucagon dual | Yes | — | Yes | Survodutide | Phase 3 |
| GLP-1 + GIP + glucagon triple | Yes | Yes | Yes | Retatrutide | Phase 3 |
What each receptor contributes:
- GLP-1 receptor: reduces appetite (central satiety), slows gastric emptying, stimulates insulin secretion, reduces glucagon (paradoxically — this is the endogenous action), protects beta cells. This is the mechanism behind semaglutide's weight loss and glycemic effects.
- GIP receptor: amplifies insulin secretion in response to glucose, may improve insulin sensitivity in adipose tissue, contributes additional weight-loss effects synergistically with GLP-1 in tirzepatide.
- Glucagon receptor: increases hepatic glucose output (the classical action, which you need to blunt in diabetes) but also increases resting energy expenditure, mobilizes hepatic fat by driving fatty-acid oxidation in the liver, and reduces appetite through central effects. The glucose-raising effect is offset in a dual agonist by the stronger GLP-1 signal, leaving the energy expenditure and liver fat benefits.
The rationale for a GLP-1/glucagon dual agonist is that glucagon's effect on the liver is uniquely well-suited to MASH, where the problem is literally too much fat in hepatocytes. A drug that combines appetite suppression (GLP-1) with direct hepatic fat mobilization (glucagon) should, in theory, outperform GLP-1 alone for liver-fat endpoints. Whether it beats tirzepatide (GLP-1/GIP) and retatrutide (triple agonist) on weight loss is the other open question.
The Clinical and Experimental Evidence
Phase 2 obesity trial. A randomized, double-blind, placebo-controlled Phase 2 trial of survodutide in 387 adults with obesity reported results in 2023 and was published with le Roux et al. (2024) in The Lancet. At 46 weeks, the highest survodutide dose produced approximately 18.7% mean placebo-adjusted body weight reduction, with continuing weight loss at the end of the study — meaning the weight-loss curve had not yet plateaued. For context, this is competitive with tirzepatide's 46-week numbers and substantially above semaglutide's.
Phase 2 MASH trial. The headline-grabbing trial was the Phase 2 MASH study, with primary results reported by Sanyal et al. (2024) in The New England Journal of Medicine. Survodutide was tested at multiple doses in patients with biopsy-confirmed MASH and stage F1–F3 liver fibrosis. The primary endpoint was histological improvement in MASH without worsening of fibrosis at 48 weeks. Survodutide-treated patients achieved the primary endpoint at rates of roughly 83% at the top dose versus 18% on placebo, with meaningful improvements in liver fibrosis as a secondary endpoint. These are strong numbers in a therapeutic area where histological endpoints are notoriously hard to move.
Phase 2 type 2 diabetes trial. A separate Phase 2 trial in patients with type 2 diabetes reported HbA1c reductions consistent with a strong GLP-1 effect plus weight loss. As expected, the glucagon component did not blunt glycemic benefits because the GLP-1 effect dominates.
Phase 3 SYNCHRONIZE program. The Phase 3 obesity development plan is the SYNCHRONIZE program, with multiple large trials covering obesity alone, obesity with type 2 diabetes, and cardiovascular outcomes. Readouts are expected across 2026 and 2027. A separate Phase 3 MASH trial is also underway.
Adverse events. The tolerability profile seen in Phase 2 was broadly consistent with the GLP-1 class — nausea, vomiting, diarrhea — with some suggestion that the dose-titration schedule matters more than for pure GLP-1 drugs, likely because the glucagon component can transiently affect heart rate and blood pressure.
Applications
If survodutide reaches approval, the likely clinical applications are:
- Obesity (primary indication). Positioned as a once-weekly subcutaneous injection, competitive with tirzepatide on weight-loss magnitude.
- MASH with fibrosis. This is where the dual mechanism may give survodutide a unique edge. MASH is a huge unmet need — an estimated 5% of the US population has it — and the field has spent a decade watching drug after drug fail Phase 3 liver-histology endpoints.
- Type 2 diabetes with obesity. Likely an add-on or alternative where the liver-fat and weight components matter.
- Cardiometabolic disease broadly. If the SELECT-style CV outcomes trials (being run as part of SYNCHRONIZE) show benefit, survodutide would move into the same general category as semaglutide and tirzepatide for reducing cardiovascular events in patients with obesity.
Connection to Gene Editing
Incretin peptide drugs and gene editing intersect in two ways that are worth drawing out.
The first is genetic validation of the drug targets. Glucagon receptor biology has been shaped by human genetics and, more recently, by CRISPR knockout experiments in mice and in hepatocyte organoids. Understanding why glucagon receptor antagonism alone causes unwanted side effects, while dual GLP-1/glucagon agonism harnesses the energy-expenditure benefit without the glycemic downside, is the kind of mechanistic question that modern gene-editing tools have helped answer preclinically.
The second, more forward-looking connection is to gene therapies for metabolic disease. Companies are actively exploring whether one-time gene therapies could achieve durable control of weight and metabolic health by editing liver or adipose cells to produce GLP-1 or related incretins endogenously — essentially an "installed" GLP-1 drug that does not require weekly injection. Survodutide-style dual pharmacology is helpful for the pharmacology question in parallel. For the foundational science, our CRISPR complete guide is the best starting point.
And if you want the broader aging and metabolism context, the way that obesity drugs have begun to show benefits on cardiovascular mortality, liver disease, and kidney disease fits naturally into the multi-organ framework of the hallmarks of aging, particularly the "deregulated nutrient sensing" and "altered intercellular communication" hallmarks.
Limitations and Regulatory Status
Some honest caveats on survodutide:
- Still investigational. No approval exists. Phase 3 could still disappoint — the gap between Phase 2 and Phase 3 in obesity has been forgiving so far, but that is not guaranteed to hold.
- Tolerability at high doses. The glucagon component adds a layer of potential side effects beyond the GLP-1 class — transient heart rate increases, mild blood pressure changes — and whether this affects real-world adherence is an open question.
- Competitive pipeline. Survodutide is entering a market where semaglutide (Wegovy) and tirzepatide (Zepbound) are already approved, and retatrutide (the Eli Lilly triple agonist) is showing Phase 2 weight-loss numbers in the mid-20s percent range. Being third or fourth to market with competitive but not dominant efficacy is a harder commercial position than being first.
- MASH commercial uncertainty. Even with strong histology data, the MASH market has proved hard to monetize; reimbursement, diagnosis, and patient identification remain obstacles.
- Cost. Like other once-weekly incretin analogs, survodutide will likely launch at prices comparable to Wegovy and Zepbound, which has strained payers globally.
FAQ
What is BI 456906?
BI 456906 is the development code for survodutide, used by Boehringer Ingelheim in early clinical trials and scientific publications.
How does survodutide differ from semaglutide?
Semaglutide activates only the GLP-1 receptor. Survodutide activates both the GLP-1 receptor and the glucagon receptor, which adds effects on energy expenditure and hepatic fat metabolism.
How does it compare to tirzepatide?
Tirzepatide is a GLP-1/GIP dual agonist (different second receptor). Survodutide's second receptor is glucagon, which is better matched to liver disease and adds an energy-expenditure component. On weight loss alone, early data suggest survodutide is competitive with tirzepatide but a direct head-to-head trial has not been run.
What about retatrutide?
Retatrutide is Eli Lilly's triple agonist (GLP-1 + GIP + glucagon) and is also in Phase 3. It is surveiled by Boehringer and Zealand as the main high-efficacy competitor. The two drugs are likely to end up in the same conversation.
When could survodutide be approved?
The Phase 3 SYNCHRONIZE obesity readouts are expected across 2026–2027, with an MASH Phase 3 on a similar or slightly later timeline. If data holds, regulatory submissions would follow in the late 2020s.
Is it safe for people without obesity?
Survodutide has not been studied in normal-weight populations. Like other incretin drugs, it is being developed for specific diseases and is not intended for cosmetic weight loss.
